GÜLTEN ÖZDEMİR, ÇİĞDEM ÇINAR, TUĞBA ŞAHBAZ, KADRİYE ÖNEŞ, YELDA SOLUK ÖZDEMİR, AYNUR METİN TERZİBAŞIOĞLU
Comprehensive Medicine - 2025;17(2):130-135
INTRODUCTION: Migraine patients have a high risk of developing anxiety and depression, and the relationship between chronic migraine (CM) and depression is believed to be bidirectional. This study aims to evaluate the effects of Botulinum Neurotoxin A (BoNT/A) treatment on migraine-related disability, pain severity, and depression in patients with CM. METHODS: This study included 24 patients aged between 19 and 55 years who were diagnosed with CM and treated with BoNT/A injections every 12 weeks for six months. Data were collected on demographic characteristics, as well as disability severity, pain severity, and depression levels before and after treatment. Results: A statistically significant improvement was observed in VAS (Visual Analog Scale), MIDAS (Migraine Disability Assessment Scale), and BDS (Beck Depres-sion Scale) scores after BoNT/A treatment (p<0.001). The mean changes in scores were as follows: a 4±1-point reduction in VAS, a 61±23-point reduction in MIDAS, and a 16±9-point reduction in BDS. Patients reported experiencing initial treatment benefits within 12±3 days, with an average duration of effect lasting 93±38 days. DISCUSSION AND CONCLUSION: BoNT/A treatment appears to play a significant role in modulating pain perception and emotional responses, particularly in patients with de-pression and those resistant to conventional migraine treatments. The findings suggest that BoNT/A may be an effective treatment option for reducing mi-graine-related disability, pain severity, and associated depressive symptoms.
